First generic versions of Vyvanse gain FDA approval

FDA has approved several first generics of Vyvanse (lisdexamfetamine dimesylate) capsules and chewable tablets for ADHD in patients six years and older and moderate to severe binge-eating disorder (BED) in adults. The prescribing information for lisdexamfetamine dimesylate contains a boxed warning about the drug's potential risk of abuse and dependence.